icon fsr

文献詳細

雑誌文献

臨床泌尿器科77巻5号

2023年04月発行

特集 どこまで変わるの? 腎細胞癌診療の進歩

〈手術療法〉

Cytoreductive nephrectomyの現状

著者: 田中一1

所属機関: 1東京医科歯科大学大学院 医歯学総合研究所 腎泌尿器外科学教室

ページ範囲:P.348 - P.354

文献概要

▶ポイント

・近年,薬物治療の進歩に伴い,転移性腎細胞癌における腫瘍減量腎摘除(CN)の位置付けが変化している.

・CNは,薬物治療に先行して施行されるimmediate CNと,薬物治療導入後に待機的に施行するdeferred CNに分けられる.現在,immediate CNの適応は,全身状態良好,予後良好,転移巣が少数かつ小さい一部の症例に限られる.薬物治療を先行させたうえで,適切な症例選択に基づくdeferred CNが検討される.

・免疫チェックポイント阻害薬におけるCNの意義については,現時点で十分なエビデンスがなく,今後の検討が待たれる.

参考文献

1) Motzer RJ, et al : Conditional Survival and Long-Term Efficacy with Nivolumab plus Ipilimumab versus Sunitinib in Patients with Advanced Renal Cell Carcinoma. Cancer 128 : 2085-2097, 2022
2) Powles T, et al : Pembrolizumab plus Axitinib versus Sunitinib Monotherapy as First-Line Treatment of Advanced Renal Cell Carcinoma (KEYNOTE-426) : Extended Follow-Up from a Randomised, Open-Label, Phase 3 Trial. Lancet Oncol 21 : 1563-1573, 2020
3) Motzer RJ, et al : Nivolumab plus Cabozantinib versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma (CheckMate 9ER) : Long-Term Follow-Up Results from an Open-Label, Randomised, Phase 3 Trial. Lancet Oncol 23 : 888-898, 2022
4) Motzer R, et al : Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 384 : 1289-1300, 2021
5) Choueiri TK, et al : Updated Efficacy Results from the JAVELIN Renal 101 Trial : First-Line Avelumab plus Axitinib versus Sunitinib in Patients with Advanced Renal Cell Carcinoma. Ann Oncol 31 : 1030-1039, 2020
6) 日本泌尿器科学会 (編) : 腎癌診療ガイドライン2017年版. 2019年アップデート. メディカルビュー社, 東京, 2019 https://www.urol.or.jp/lib/files/other/guideline/33_renal_cancer_2017_rev2019_info.pdf (2023年3月10日閲覧)
7) EAU Guidelines on Renal Cell Carcinoma. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carinoma-2022.pdf (2023年3月10日閲覧)
). Kidney Cancer, Version 3.2023 https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (2023年3月10日閲覧)
9) Basappa NS, et al : The Impact of Tumor Burden Characteristics in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Cancer 117 : 1183-1189, 2011
10) Iacovelli R, et al : Tumour Burden Is an Independent Prognostic Factor in Metastatic Renal Cell Carcinoma. BJU Int 110 : 1747-1753, 2012
11) Escudier B, et al : Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma : Subanalyses by Prior Therapy from a Randomised Phase III Trial. Br J Cancer 110 : 2821-2828, 2014
12) Bhindi B, et al : Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond : An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 75 : 111-128, 2019
13) Gershman B, et al : Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. Eur Urol 69 : 84-91, 2016
14) Flanigan RC, et al : Nephrectomy Followed by Interferon-Alfa-2b Compared with Lnterferon Alfa-2b Alone for Metastatic Renal-Cell Cancer. N Engl J Med 345 : 1655-1659, 2001
15) Mickisch GH, et al : Radical Nephrectomy plus Interferon-Alfa-Based Immunotherapy Compared with Interferon-Alfa Alone in Metastatic Renal-Cell Carcinoma : A Randomised Trial. Lancet 358 : 966-970, 2001
16) Flanigan RC, et al : Cytoreductive Nephrectomy in Patients with Metastatic Renal Cancer : A Combined Analysis. J Urol 171 : 1071-1076, 2004
17) Méjean A, et al : Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med 379 : 417-427, 2018
18) Méjean A, et al : Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma : Is There Still a Role for Cytoreductive Nephrectomy? Eur Urol 80 : 417-424, 2021
19) Bex A, et al : Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib : The SURTIME Randomized Clinical Trial. JAMA Oncol 5 : 164-170, 2019
20) Motzer RJ, et al : Nivolumab plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma : Extended Follow-Up of Efficacy and Safety Results from a Randomised, Controlled, Phase 3 Trial. Lancet Oncol 20 : 1370-1385, 2019
21) Ishihara H, et al : Association of Tumor Burden with Outcome in First-Line Therapy with Nivolumab plus Ipilimumab for Previously Untreated Metastatic Renal Cell Carcinoma. Jpn J Clin Oncol 51 : 1751-1756, 2021
22) Sharma P, et al : Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168 : 707-723, 2017
23) Hirsch L, et al : Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. Drugs 80 : 1169-1181, 2020
24) Mori K, et al : The Effect of Immune Checkpoint Inhibitor Combination Therapies in Metastatic Renal Cell Carcinoma Patients with and without Previous Cytoreductive Nephrectomy : A Systematic Review and Meta-Analysis. Int Immunopharmacol 108 : 108720, 2022
25) Bell H, et al : “PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Kidney Cancer J 6 : 3-9, 2022
26) Isali I, et al : Role of Cytoreductive Surgery in the Era of Immunotherapy. Curr Opin Urol 32 : 618-626, 2022
27) Albiges L, et al : First-Line Nivolumab plus Ipilimumab versus Sunitinib in Patients without Nephrectomy and with an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol 81 : 266-271, 2022
28) Grünwald V, et al : Analysis of the CLEAR Study in Patients (pts) with Advanced Renal Cell Carcinoma (RCC) : Depth of Response and Efficacy for Selected Subgroups in the Lenvatinib (LEN) + Pembrolizumab (PEMBRO) and Sunitinib (SUN) Treatment Arms. J Clin Oncol 39 (Suppl) : 4560, 2021
29) Kikuchi H, et al : Efficacy of Nivolumab plus Ipilimumab as First-Line Therapy for Primary Tumors in Patients with Renal Cell Carcinoma. Urol Oncol 40 : 13.e19-13.e27, 2022

掲載誌情報

出版社:株式会社医学書院

電子版ISSN:1882-1332

印刷版ISSN:0385-2393

雑誌購入ページに移動
icon up

本サービスは医療関係者に向けた情報提供を目的としております。
一般の方に対する情報提供を目的としたものではない事をご了承ください。
また,本サービスのご利用にあたっては,利用規約およびプライバシーポリシーへの同意が必要です。

※本サービスを使わずにご契約中の電子商品をご利用したい場合はこちら